EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study

Caifeng Li, Junmei Zhang, Haiguo Yu, Meiping Lu, Sirui Yang, Cuihua Liu, Ping Zeng, Bo Zhao, Xiaoqing Li, Wenjie Zheng, Yue Du, Wei Zhang und 8 weitere

Rheumatology and Therapy · 2026-06 · 13 (3) · 595-610

DOI: 10.1007/s40744-026-00830-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 11.03.2026. Verfasst von Caifeng Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, Beijing, China. caifeng_li@yeah.net. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Changchun GeneScience Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder that impacts children aged ≤ 16 years. This study evaluated the efficacy and safety of firsekibart, a fully human anti-IL-1β monoclonal antibody, in children with active sJIA. METHODS: This multicenter, randomized, open-label, active-controlled phase 2 study (NCT05925452) enrolled participants aged 2- < 18 years with active sJIA across 14 sites in China. Participants were randomized (1:1:1) to firsekibart 3.0 mg/kg or 4.0 mg/kg subcutaneously every 4 weeks, or tocilizumab intravenously every 2 weeks, for 24 weeks. The primary endpoint was modified JIA American College of Rheumatology Pediatric criteria (ACR Pedi) 30 response at day 28. Secondary endpoints included ACR Pedi 30/50/70/90 responses, corticosteroid tapering, immunogenicity, and safety. RESULTS: Fifty participants were randomized (firsekibart 3.0 mg/kg: n = 17; 4.0 mg/kg: n = 16; tocilizumab: n = 17). At day 28, ACR Pedi 30 response rates were 94.1% (95% CI 71.3-99.9), 75.0% (47.6-92.7) and 82.4% (56.6-96.2) in the firsekibart 3.0 mg/kg, 4.0 mg/kg, and tocilizumab groups, respectively. Firsekibart 3.0 mg/kg achieved numerically higher ACR Pedi 70/90 responses. By the end of treatment, successful corticosteroid tapering occurred in 75.0%, 63.6%, and 62.5% of patients receiving firsekibart 3.0 mg/kg, 4.0 mg/kg, and tocilizumab, respectively. No MAS events or anti-drug or neutralizing antibodies were detected. Treatment-emergent adverse events (TEAEs) occurred in 70.6%, 93.8%, and 94.1% of participants in the firsekibart 3.0 mg/kg, 4.0 mg/kg, and tocilizumab groups, respectively. Grade ≥ 3 TEAEs were absent in the 3.0 mg/kg group. Common TEAEs mainly included infections and laboratory abnormalities. CONCLUSIONS: Firsekibart demonstrated rapid clinical improvement, steroid-sparing effects, and an acceptable safety profile. The 3.0 mg/kg dose provided the most favorable benefit-risk balance, with efficacy and safety outcomes comparable to tocilizumab, supporting further evaluation as a convenient once-every-4-weeks IL-1β-targeted option in future phase 3 trials. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT05925452.

Schlagwörter

Stichwörter der Autor:innen

FirsekibartInterleukin-1β (IL-1β)Phase 2 studySystemic juvenile idiopathic arthritis

Autor:innen und Institutionen

  • Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, Beijing, China. caifeng_li@yeah.net.
  • Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
  • Children's Hospital of Nanjing Medical University, Nanjing, China.
  • Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
  • The First Hospital of Jilin University, Changchun, China.
  • Henan Children's Hospital Zhengzhou Children's Hospital, Zhengzhou, China.

Förderung

  • Changchun GeneScience Pharmaceutical Co., Ltd.

Zitieren

APA

Li, C., Zhang, J., Yu, H., Lu, M., Yang, S., Liu, C., Zeng, P., Zhao, B., Li, X., Zheng, W., Du, Y., Zhang, W., Li, Z., Hu, X., Lai, J., Xu, Q., Zhang, X., Wang, X., Adili, P., & Qu, W. (2026). Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study. Rheumatology and Therapy, 13(3), 595-610. https://doi.org/10.1007/s40744-026-00830-9

Vancouver

Li C, Zhang J, Yu H, Lu M, Yang S, Liu C, et al. Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study. Rheumatology and Therapy. 2026;13(3):595-610. doi:10.1007/s40744-026-00830-9

BibTeX
@article{Li2026,
  author = {Li, Caifeng and Zhang, Junmei and Yu, Haiguo and Lu, Meiping and Yang, Sirui and Liu, Cuihua and Zeng, Ping and Zhao, Bo and Li, Xiaoqing and Zheng, Wenjie and Du, Yue and Zhang, Wei and Li, Zhihui and Hu, Xiufen and Lai, Jianming and Xu, Qian and Zhang, Xu and Wang, Xianyang and Adili, Palasaiti and Qu, Wei},
  title = {Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study},
  journal = {Rheumatology and Therapy},
  year = {2026},
  volume = {13},
  number = {3},
  pages = {595--610},
  doi = {10.1007/s40744-026-00830-9}
}
Kostenlos starten →